Full text

Turn on search term navigation

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Several mutations of the uppermost arginine, R219, in the voltage-sensing sliding helix S4I of cardiac sodium channel Nav1.5 are reported in the ClinVar databases, but the clinical significance of the respective variants is unknown (VUSs). AlphaFold 3 models predicted a significant downshift of S4I in the R219C VUS. Analogous downshift S4I, upon its in silico deactivation, resulted in a salt bridge between R219 and the uppermost glutamate, E161, in helix S2I. To understand how salt bridge elimination affects biophysical characteristics, we generated mutant channel R219E, expressed it in the HEK293-T cells, and employed the patch-clamp method in a whole-cell configuration. Mutation R219E did not change the peak current density but shortened time to the peak current at several potentials, significantly enhanced activation, enhanced steady-state inactivation and steady-state fast inactivation, and slowed recovery from inactivation. Taken together, these data suggest that mutation R219E destabilized the resting state of Nav1.5. Cardiac syndromes associated with mutations R219P/H/C/P or E161Q/K are consistent with the observed changes of biophysical characteristics of mutant channel R219E suggesting pathogenicity of the respective VUSs, as well as ClinVar-reported VUSs involving arginine or glutamate in homologous positions of several Nav1.5 paralogs.

Details

Title
Charge Reversal of the Uppermost Arginine in Sliding Helix S4-I Affects Gating of Cardiac Sodium Channel
Author
Kulichik, Olga E 1   VIAFID ORCID Logo  ; Zaytseva, Anastasia K 2 ; Kostareva, Anna A 3   VIAFID ORCID Logo  ; Zhorov, Boris S 4   VIAFID ORCID Logo 

 Almazov National Medical Research Centre, 197341 St. Petersburg, Russia; [email protected] (O.E.K.); [email protected] (A.K.Z.); [email protected] (A.A.K.) 
 Almazov National Medical Research Centre, 197341 St. Petersburg, Russia; [email protected] (O.E.K.); [email protected] (A.K.Z.); [email protected] (A.A.K.); Sechenov Institute of Evolutionary Physiology & Biochemistry, Russian Academy of Sciences, 194223 St. Petersburg, Russia 
 Almazov National Medical Research Centre, 197341 St. Petersburg, Russia; [email protected] (O.E.K.); [email protected] (A.K.Z.); [email protected] (A.A.K.); Department of Women’s and Children’s Health and Center for Molecular Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden 
 Almazov National Medical Research Centre, 197341 St. Petersburg, Russia; [email protected] (O.E.K.); [email protected] (A.K.Z.); [email protected] (A.A.K.); Sechenov Institute of Evolutionary Physiology & Biochemistry, Russian Academy of Sciences, 194223 St. Petersburg, Russia; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada 
First page
712
Publication year
2025
Publication date
2025
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3159504872
Copyright
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.